RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
收藏NIAID Data Ecosystem2026-05-01 收录
官方服务：
资源简介：
This is an open-label, nonrandomized, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma.
创建时间：
2023-06-15
